What do systematic reviews say?

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 294 participants
  Moderate

Beta‐2 agonists vs placebo

The review found no eligible studies for this question.

• Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

LAMA vs placebo

• Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 974 participants
  Low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Low

C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 374 participants
  Low

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 130 participants
  Moderate

Plasma‐derived C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Low

Avoralstat vs placebo

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 93 participants
  Moderate

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Summary of findings: aztreonam lysine for inhalation vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 268 participants
  Moderate

Fixed‐dose combination aclidinium/formoterol vs placebo

Fixed‐dose combination aclidinium/formoterol leads to higher quality of life: number of participants with clinically significant… compared with placebo (high certainty).

• Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 1.72 [1.39, 2.13]
  2 studies · 1823 participants
  High

Fixed‐dose combination aclidinium/formoterol vs aclidinium alone

Fixed‐dose combination aclidinium/formoterol showed no clear difference in quality of life: number of participants with clinically significant… compared with aclidinium alone (moderate certainty).

• Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 1.17 [0.97, 1.41]
  2 studies · 2002 participants
  Moderate

Fixed‐dose combination aclidinium/formoterol vs formoterol

Fixed‐dose combination aclidinium/formoterol showed no clear difference in quality of life: number of participants with clinically significant… compared with formoterol (low certainty).

• Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
  OR 1.15 [0.89, 1.5]
  1 study · 1000 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 454 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1042 participants
  Very low

Psychological therapy vs any non‐therapy comparator: end‐of‐intervention and short‐term follow‐up

• Psychological therapies for depression in older adults residing in long‐term care settings 2024 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 195 participants
  Very low

ICU follow‐up services vs standard care or no follow‐up service

• Follow‐up services for improving long‐term outcomes in intensive care unit (ICU) survivors 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 286 participants
  Low

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1013 participants
  Low